PRINCETON, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage…
SYDNEY, AUSTRALIA, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology…
CAPLYTA Q2 2024 net product sales were $161.3 million, compared to $110.1 million for the same period in 2023, representing a…
NEW YORK, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical…
LOS ANGELES, Aug. 6, 2024 /PRNewswire/ -- Nammi Therapeutics, Inc. (Nammi) announces a $1M investment commitment by the Myeloma Investment…
- Promising Phase 1/2 SNS-101 clinical data presented at ASCO 2024 - - Enrollment in the Phase 1 dose expansion…
Call Scheduled for Thursday, August 15, 2024, at 9:00 a.m. ETDENVER--(BUSINESS WIRE)--TriSalus Life Sciences® Inc., (Nasdaq: TLSI), an oncology company…
Soquelitinib registrational Phase 3 clinical trial in PTCL advancing toward initial enrollment in Q3 2024 Fast track designation underscores unmet…
NORCROSS, Ga., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target…
Company to initiate Phase 3 VERSATILE-003 trial in Q4 2024 Conference Call Today at 8:00 a.m. Eastern Time PRINCETON, N.J.,…